Compare AEO & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEO | BEAM |
|---|---|---|
| Founded | 1977 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2004 | 2019 |
| Metric | AEO | BEAM |
|---|---|---|
| Price | $17.90 | $24.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 15 |
| Target Price | $18.55 | ★ $52.15 |
| AVG Volume (30 Days) | ★ 6.2M | 1.8M |
| Earning Date | 09-09-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $5,547,236,000.00 | $24,000.00 |
| Revenue This Year | $5.54 | N/A |
| Revenue Next Year | $3.42 | $29.19 |
| P/E Ratio | $19.88 | ★ N/A |
| Revenue Growth | 4.10 | ★ 33.33 |
| 52 Week Low | $14.06 | $20.23 |
| 52 Week High | $28.46 | $38.26 |
| Indicator | AEO | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 44.05 |
| Support Level | $16.87 | $24.30 |
| Resistance Level | $18.50 | $26.50 |
| Average True Range (ATR) | 0.62 | 1.12 |
| MACD | 0.33 | 0.08 |
| Stochastic Oscillator | 85.52 | 54.18 |
American Eagle Outfitters Inc is a specialty retailer. The company is engaged in the retail of apparel and accessories with company stores in the United States, Canada, Mexico, and Hong Kong. The Company leases all store premises, regional distribution facilities, some of its office space, and certain information technology and office equipment. American Eagle also has its online business. It operates in two segments: American Eagle and Aerie. The majority of its revenue comes from its primary brand, American Eagle, which offers an assortment of specialty apparel, accessories, and personal care products for women and men. Geographically, it generates the majority of its revenue from the United States.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.